Said enzyme is one which catalyzes oxidation of nucleoside to yield nucleoside-5'-carboxylic acid via nucleoside-5'-aldehyde by the reaction between the nucleoside and molecular oxygen without producing hydrogen peroxide.
The oligonucleotide comprises a nucleoside labeled with a fluorophore and at least one neighboring nucleoside positioned next to the fluorophore-labeled nucleoside, the nucleobase of the neighboring nucleoside being thymine or cytosine.
Suitable reagents include nucleoside phosphoramidite and nucleoside hydrogen phosphonate.
The invention relates to specific nucleosides and also to medicaments which comprise these nucleosides.
The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase.
The nucleocide analogue is one represented by the following formula (I) or a salt thereof.
Modified dimers having a ribose sugar moiety in the 5' nucleoside and a 2' modified sugar in the 3' nucleoside are provided.
Pyrimidine nucleoside 5'-triphosphoric acid is converted into pyrimidine nucleoside 5'-(cyclic triphosphoric acid) with a condensation agent.
Disclosed is a method for separating and purifying a nucleoside or nucleotide from a culture solution containing the nucleoside or nucleotide.
The compounds comprise a nucleoside or nucleoside analog linked, commonly through a phosphate group to one of a selected group of lipids.
Provided are prodrugs of pyrrolo[l,2-f][l,2,4]triazin-7-yl nucleoside phosphates wherein the 1 ' position of the nucleoside sugar is substituted with CN.
The enzyme incorporates derivatized nucleoside triphosphates with high efficiency.
Novel nucleoside analog compounds are disclosed.
Finally, the use of a farmaceutical composition to cure a subject suffering from a HBV infection, which HBV is resistant to lamuvidine and/or adefovir has been provided, which farmaceutical composition comprises the nucleoside analogue tenofovir.